InvestorsHub Logo
Followers 1
Posts 54
Boards Moderated 0
Alias Born 04/01/2017

Re: None

Tuesday, 04/11/2017 8:20:41 PM

Tuesday, April 11, 2017 8:20:41 PM

Post# of 2719
Would someone with a whole lot more business sense than me, please look at Aurinia Pharmaceuticals (AUPH) recent move. I believe they called it a secondary offering. The share price was approx. $10.50 and their secondary stock offering was for $6.75 per share. Since that action the price has been just over $7, which angered many shareholders. AUPH justified this secondary offering by saying that they needed to fund their 3rd phase of testing. Which I tend to believe. Would this move by Cytori have the same motivation?